Literature DB >> 28374254

Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.

Pan Tao1, Qin Li1, Sathish B Shivachandra1, Venigalla B Rao2.   

Abstract

Protein-based subunit vaccines represent a safer alternative to the whole pathogen in vaccine development. However, limitations of physiological instability and low immunogenicity of such vaccines demand an efficient delivery system to stimulate robust immune responses. The bacteriophage T4 capsid-based antigen delivery system can robustly elicit both humoral and cellular immune responses without any adjuvant. Therefore, it offers a strong promise as a novel antigen delivery system. Currently Bacillus anthracis, the causative agent of anthrax, is a serious biothreat agent and no FDA-approved anthrax vaccine is available for mass vaccination. Here, we describe a potential anthrax vaccine using a T4 capsid platform to display and deliver the 83 kDa protective antigen, PA, a key component of the anthrax toxin. This T4 vaccine platform might serve as a universal antigen delivery system that can be adapted to develop vaccines against any infectious disease.

Entities:  

Keywords:  Anthrax vaccine; Bacteriophage T4; Nanoparticle vaccine platform; PA; Virus decoration proteins

Mesh:

Substances:

Year:  2017        PMID: 28374254      PMCID: PMC5753585          DOI: 10.1007/978-1-4939-6869-5_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  23 in total

1.  Molecular architecture of the prolate head of bacteriophage T4.

Authors:  Andrei Fokine; Paul R Chipman; Petr G Leiman; Vadim V Mesyanzhinov; Venigalla B Rao; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

Review 2.  Structure, assembly, and DNA packaging of the bacteriophage T4 head.

Authors:  Lindsay W Black; Venigalla B Rao
Journal:  Adv Virus Res       Date:  2012       Impact factor: 9.937

3.  Multicomponent anthrax toxin display and delivery using bacteriophage T4.

Authors:  Sathish B Shivachandra; Qin Li; Kristina K Peachman; Gary R Matyas; Stephen H Leppla; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Vaccine       Date:  2006-10-17       Impact factor: 3.641

4.  Bacteriophage T4 capsid: a unique platform for efficient surface assembly of macromolecular complexes.

Authors:  Qin Li; Sathish B Shivachandra; Stephen H Leppla; Venigalla B Rao
Journal:  J Mol Biol       Date:  2006-08-23       Impact factor: 5.469

5.  In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine.

Authors:  Pan Tao; Marthandan Mahalingam; Bernard S Marasa; Zhihong Zhang; Ashok K Chopra; Venigalla B Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 6.  Vaccines: countering anthrax: vaccines and immunoglobulins.

Authors:  John D Grabenstein
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

Review 7.  Anthrax vaccines: present status and future prospects.

Authors:  Manpreet Kaur; Samer Singh; Rakesh Bhatnagar
Journal:  Expert Rev Vaccines       Date:  2013-08       Impact factor: 5.217

8.  Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against Yersinia pestis.

Authors:  Pan Tao; Marthandan Mahalingam; Venigalla B Rao
Journal:  Methods Mol Biol       Date:  2016

9.  Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Authors:  Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Julie Lovchik; Rick C Lyons; Carl R Alving; Venigalla B Rao; Mangala Rao
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

10.  Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.

Authors:  Pan Tao; Marthandan Mahalingam; Michelle L Kirtley; Christina J van Lier; Jian Sha; Linsey A Yeager; Ashok K Chopra; Venigalla B Rao
Journal:  PLoS Pathog       Date:  2013-07-11       Impact factor: 6.823

View more
  8 in total

Review 1.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

2.  Engineering of Bacteriophage T4 Genome Using CRISPR-Cas9.

Authors:  Pan Tao; Xiaorong Wu; Wei-Chun Tang; Jingen Zhu; Venigalla Rao
Journal:  ACS Synth Biol       Date:  2017-07-13       Impact factor: 5.110

Review 3.  Bacteriophage Capsid Modification by Genetic and Chemical Methods.

Authors:  Caitlin M Carmody; Julie M Goddard; Sam R Nugen
Journal:  Bioconjug Chem       Date:  2021-03-04       Impact factor: 4.774

4.  A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.

Authors:  Pan Tao; Marthandan Mahalingam; Jingen Zhu; Mahtab Moayeri; Jian Sha; William S Lawrence; Stephen H Leppla; Ashok K Chopra; Venigalla B Rao
Journal:  mBio       Date:  2018-10-16       Impact factor: 7.867

Review 5.  Genetic Engineering of Bacteriophages Against Infectious Diseases.

Authors:  Yibao Chen; Himanshu Batra; Junhua Dong; Cen Chen; Venigalla B Rao; Pan Tao
Journal:  Front Microbiol       Date:  2019-05-03       Impact factor: 5.640

6.  Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.

Authors:  Mengling Li; Pengju Guo; Cen Chen; Helong Feng; Wanpo Zhang; Changqin Gu; Guoyuan Wen; Venigalla B Rao; Pan Tao
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 8.786

7.  Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9.

Authors:  Pan Tao; Xiaorong Wu; Venigalla Rao
Journal:  Sci Adv       Date:  2018-02-14       Impact factor: 14.136

8.  Specific Integration of Temperate Phage Decreases the Pathogenicity of Host Bacteria.

Authors:  Yibao Chen; Lan Yang; Dan Yang; Jiaoyang Song; Can Wang; Erchao Sun; Changqin Gu; Huanchun Chen; Yigang Tong; Pan Tao; Bin Wu
Journal:  Front Cell Infect Microbiol       Date:  2020-02-04       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.